[Treatment of hypotension complicating pregnancy improves fetal outcome].
A prospective study 30 out of 60 pregnant women suffering from pathologic hypotension were treated regularly with the mineralocorticoid 11-Desoxycorticosteronönanthat (Cortiron (R)-Depot). To the other 30 women no medication was given --they served as a control-group. In order to get information on the uteroplacental perfusion rate, placental flow measurements using radioisotopes were carried out. In comparison with the untreated blood-pressure and placental perfusion in the medicated pregnant women was significantly higher. The investigation of the fetal outcome showed 600 g heavier neonates in the mineralocorticoid treated group; the rate of dystrophy was significantly lower. The results entitle the requirement of medication in cases of maternal hypotension (RR 110/65 mm Hg and below). By our experiences we can recommend the mineralocorticoid Cortiron (R)-Depot.
D000328:Adult; D001724:Birth Weight; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D003900:Desoxycorticosterone / Q000008:administration & dosage*; D005260:Female; D005317:Fetal Growth Retardation / Q000517:prevention & control; D006801:Humans; D007022:Hypotension / Q000188:drug therapy*; D010920:Placenta / Q000098:blood supply; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011446:Prospective Studies
D003692:Delayed-Action Preparations; D003900:Desoxycorticosterone
Behandlung der schwangerschaftsbedingten Hypotonie verbessert kindliche Prognose.